Sunshine Biopharma (SBFM) Operating Income (2011 - 2026)

Sunshine Biopharma (SBFM) has reported Operating Income for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Income rose 21.5% year-over-year to -$1.6 million; the trailing twelve-month figure through Jun 2026 stood at -$5.9 million (up 9.38% YoY), and the FY2025 full-year result was -$6.2 million, down 7.14% from the prior year.
• Operating Income fell to -$1.6 million in Q2 2026 per SBFM's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Operating Income topped out at -$695796.0 in Q2 2022 and bottomed at -$23.4 million in Q4 2022.
• Historically, Operating Income has averaged -$2.6 million across 5 years, with a median of -$1.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Income plunged 8255.16% in 2022, then jumped 94.92% in 2023.
• Over 5 years, Operating Income stood at -$23.4 million in 2022, then surged by 94.92% to -$1.2 million in 2023, then slumped by 71.64% to -$2.0 million in 2024, then rose by 12.16% to -$1.8 million in 2025, then gained by 9.9% to -$1.6 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered -$1.6 million, -$1.4 million, and -$1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.